Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide

被引：1
作者：
Dib, Elie G. [1 ]
Antonarakis, Emmanuel S. [3 ]
Wasco, Matthew J. [2 ]
Powell, Steven F. [4 ]
机构：
[1] Trinity Hlth IHA Hematol Oncol Consultants, Ann Arbor, MI USA
[2] Trinity Hlth IHA Pathol, Ann Arbor, MI USA
[3] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Sanford Canc Ctr, Sioux Falls, SD USA
来源：
CLINICAL GENITOURINARY CANCER | 2019年 / 17卷 / 02期
关键词：
CDK12; Checkpoint inhibitor; Homologous recombination; Mismatch-repair deficiency; PDL-1; UNITED-STATES; RACE;
D O I：
10.1016/j.clgc.2018.11.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E365 / E368
页数：4
相关论文
共 16 条
  • [11] Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
    Nuhn, Philipp
    De Bono, Johann S.
    Fizazi, Karim
    Freedland, Stephen J.
    Grilli, Maurizio
    Kantoff, Philip W.
    Sonpavde, Guru
    Sternberg, Cora N.
    Yegnasubramanian, Srinivasan
    Antonarakis, Emmanuel S.
    [J]. EUROPEAN UROLOGY, 2019, 75 (01) : 88 - 99
  • [12] Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
    Rodrigues, Daniel Nava
    Rescigno, Pasquale
    Liu, David
    Yuan, Wei
    Carreira, Suzanne
    Lambros, Maryou B.
    Seed, George
    Mateo, Joaquin
    Riisnaes, Ruth
    Mullane, Stephanie
    Margolis, Claire
    Miao, Diana
    Miranda, Susana
    Dolling, David
    Clarke, Matthew
    Bertan, Claudia
    Crespo, Mateus
    Boysen, Gunther
    Ferreira, Ana
    Sharp, Adam
    Figueiredo, Ines
    Keliher, Daniel
    Aldubayan, Saud
    Burke, Kelly P.
    Sumanasuriya, Semini
    Fontes, Mariane Sousa
    Bianchini, Diletta
    Zafeiriou, Zafeiris
    Mendes, Larissa Sena Teixeira
    Mouw, Kent
    Schweizer, Michael T.
    Pritchard, Colin C.
    Salipante, Stephen
    Taplin, Mary-Ellen
    Beltran, Himisha
    Rubin, Mark A.
    Cieslik, Marcin
    Robinson, Dan
    Heath, Elizabeth
    Schultz, Nikolaus
    Armenia, Joshua
    Abida, Wassim
    Scher, Howard
    Lord, Christopher
    D'Andrea, Alan
    Sawyers, Charles L.
    Chinnaiyan, Arul M.
    Alimonti, Andrea
    Nelson, Peter S.
    Drake, Charles G.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (10) : 4441 - 4453
  • [13] Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study
    Steele, C. Brooke
    Li, Jun
    Huang, Bin
    Weir, Hannah K.
    [J]. CANCER, 2017, 123 : 5160 - 5177
  • [14] Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
    Strickland, Kyle C.
    Howitt, Brooke E.
    Shukla, Sachet A.
    Rodig, Scott
    Ritterhouse, Lauren L.
    Liu, Joyce F.
    Garber, Judy E.
    Chowdhury, Dipanjan
    Wu, Catherine J.
    D'Andrea, Alan D.
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis A.
    [J]. ONCOTARGET, 2016, 7 (12) : 13587 - 13598
  • [15] PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
    Velho, Pedro Isaacsson
    Antonarakis, Emmanuel S.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 475 - 486
  • [16] Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
    Wu, Yi-Mi
    Cieslik, Marcin
    Lonigro, Robert J.
    Vats, Pankaj
    Reimers, Melissa A.
    Cao, Xuhong
    Ning, Yu
    Wang, Lisha
    Kunju, Lakshmi P.
    de Sarkar, Navonil
    Heath, Elisabeth I.
    Chou, Jonathan
    Feng, Felix Y.
    Nelson, Peter S.
    de Bono, Johann S.
    Zou, Weiping
    Montgomery, Bruce
    Alva, Ajjai
    Robinson, Dan R.
    Chinnaiyan, Arul M.
    [J]. CELL, 2018, 173 (07) : 1770 - +
12